PURR enters the back half of August with a contradictory setup: shorts are retreating on the week, yet the one-month picture tells a story of sustained bearish accumulation that is hard to ignore.
The most striking number in the short interest data is the 38% rise in shares short over the past 30 days. That build — from roughly 17.5 million shares in early July to a peak above 26.5 million in early August — represents a sustained, deliberate bet against Hyperliquid Strategies. The stock has responded accordingly, falling 13% over the past month to $6.57. The last two days have brought partial relief: short interest dropped roughly 7% on August 11 alone, pulling back toward 24 million shares. Whether that represents profit-taking, a squeeze, or simply tactical trimming is unclear, but the reversal is real.
The lending market is loose enough that the short pressure isn't being driven by a tight borrow. Availability has eased considerably from its 52-week low — which touched just 15.6% earlier this year — and now sits near 223%, meaning more than two shares are available to borrow for every one already lent out. Cost to borrow has also fallen sharply, down 38% over the past month to a low 0.46%. That combination — ample supply, cheap borrow — gave short sellers every structural incentive to press the position over July. Options positioning is not signalling alarm either; the put/call ratio of 0.31 is close to its 20-day average and sits well below the 52-week high of 0.67, suggesting options traders are not materially more defensive than usual.
The Street backdrop is constructive on paper but increasingly dated. Cantor Fitzgerald raised its target to $18.40 on July 1, nearly doubling the prior level of $8.00 while keeping an Overweight rating. Chardan Capital maintained its Buy at $9.75 through June. At a current price of $6.57, both targets imply meaningful upside, and the consensus mean sits at $13.05. The PE multiple has compressed around 30% over the past month to roughly 9.7x, which either reflects value-creation or deteriorating earnings expectations. The analyst bull case centres on the HIP-3 launch expected in Q4, rising daily trading volumes on the Hyperliquid protocol, and EVM compatibility reducing smart contract costs. The bear case is more immediate: HYPE token weakness, aggressive competition from rivals such as Aster and edgeX, and market share erosion that has knocked the mNAV ratio materially lower. The bull/bear framing from Benzinga dates to April, so take those narratives as backdrop rather than live commentary.
Institutional flows add an interesting wrinkle. BlackRock added 8.1 million shares in the period ending July 31, lifting its stake to 10.1 million shares and 7.5% of the company. State Street added 5.9 million shares to reach 9.0 million. Both are index-driven flows in a stock that has clearly been included in relevant benchmarks, but the scale of the additions — within a context where short interest was simultaneously climbing — illustrates how directly opposing forces have been at work. Crypto-native names like Paradigm and Pantera hold smaller positions but their stasis through Q1 suggests they are not aggressively adding at current levels.
The ORTEX short score has been stable but elevated, oscillating between 61 and 64 over the past two weeks. That range signals continued bearish pressure relative to the broad market without pointing to an extreme. With no next earnings date on the calendar, the near-term catalyst calendar is sparse, placing the focus squarely on whether the short interest drawdown of the past two days is the start of a cover trade or a brief pause before the month-long build resumes.
See the live data behind this article on ORTEX.
Open PURR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
